{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:35:22Z","timestamp":1791858922358,"version":"4.3.4"},"reference-count":69,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Complement-mediated thrombotic microangiopathy can be difficult to recognize when it presents in the setting of an apparent clinical trigger, such as pregnancy, severe hypertension, or kidney transplantation. These conditions can each cause endothelial injury directly but may also unmask complement dysregulation in susceptible individuals. In these situations, the critical question is not whether a trigger exists but whether it fully explains the syndrome and whether urgent complement blockade is warranted to prevent irreversible kidney injury. In this How I Treat article, we use 3 real-world cases to illustrate how we approach this decision in practice. We emphasize the bedside features that most influence our threshold to treat, including the pattern and severity of kidney injury, tempo of disease progression, and lack of improvement with supportive or trigger-directed care. We also address the interpretation of complement genetic findings, pregnancy- and transplant-specific risk stratification, and the individualization of treatment duration. Functional assays can support mechanistic assessment in selected cases but remain an adjunct to diagnosis and should not drive management decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033525","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:54:53Z","timestamp":1784757293000},"page":"1763-1774","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["How I treat thrombotic microangiopathy in the setting of triggers"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-238X","authenticated-orcid":false,"given":"Anuja","family":"Java","sequence":"first","affiliation":[{"name":"1Division of Nephrology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-8228","authenticated-orcid":false,"given":"Meera","family":"Sridharan","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-6910","authenticated-orcid":false,"given":"Spero","family":"Cataland","sequence":"additional","affiliation":[{"name":"3Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2026100111262868500_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"2026100111262868500_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-072211-110606","article-title":"Defective complement inhibitory function predisposes to renal disease","volume":"64","author":"Java","year":"2013","journal-title":"Annu Rev Med"},{"issue":"3","key":"2026100111262868500_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"key":"2026100111262868500_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012615-044145","article-title":"Complement dysregulation and disease: insights from contemporary genetics","volume":"12","author":"Liszewski","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"2026100111262868500_bib5","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/ndt\/gfaf091","article-title":"Complement activation in secondary thrombotic microangiopathies","volume":"40","author":"Morelle","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2026100111262868500_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2026100111262868500_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/AOG.0000000000005024","article-title":"Differentiating and managing rare thrombotic microangiopathies during pregnancy and postpartum","volume":"141","author":"Lim","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2026100111262868500_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/HYPERTENSIONAHA.121.17311","article-title":"Differentiating hemolysis, elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period","volume":"78","author":"Burwick","year":"2021","journal-title":"Hypertension"},{"issue":"4","key":"2026100111262868500_bib9","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"2026100111262868500_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.preghy.2018.02.007","article-title":"Thrombotic microangiopathies of pregnancy: differential diagnosis","volume":"12","author":"Gupta","year":"2018","journal-title":"Pregnancy Hypertens"},{"issue":"8","key":"2026100111262868500_bib11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.ekir.2024.05.016","article-title":"Thrombotic microangiopathy in pregnancy: current understanding and management strategies","volume":"9","author":"Urra","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"2","key":"2026100111262868500_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2026100111262868500_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/diagnostics14040352","article-title":"HELLP syndrome and differential diagnosis with other thrombotic microangiopathies in pregnancy","volume":"14","author":"Giannubilo","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026100111262868500_bib14","doi-asserted-by":"crossref","first-page":"1343060","DOI":"10.3389\/fmed.2024.1343060","article-title":"Pregnancy as a susceptible state for thrombotic microangiopathies","volume":"11","author":"Frimat","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026100111262868500_bib15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/asheducation-2015.1.644","article-title":"Syndromes of thrombotic microangiopathy associated with pregnancy","volume":"2015","author":"George","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2026100111262868500_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajog.2008.03.011","article-title":"Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006","volume":"199","author":"Martin","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2026100111262868500_bib17","first-page":"325","article-title":"Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026100111262868500_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/ijerph16010109","article-title":"Diagnosis of HELLP syndrome: a 10-year survey in a perinatology centre","volume":"16","author":"Rimaitis","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"2026100111262868500_bib19","doi-asserted-by":"crossref","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"2026100111262868500_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"5","key":"2026100111262868500_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1681\/ASN.2010030308","article-title":"Pulling the trigger in atypical hemolytic uremic syndrome: the role of pregnancy","volume":"21","author":"Goodship","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2026100111262868500_bib22","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40620-021-01025-x","article-title":"Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a global aHUS registry analysis","volume":"34","author":"Fakhouri","year":"2021","journal-title":"J Nephrol"},{"issue":"5","key":"2026100111262868500_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"2026100111262868500_bib24","doi-asserted-by":"crossref","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"issue":"9","key":"2026100111262868500_bib25","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin Kidney J"},{"issue":"18","key":"2026100111262868500_bib26","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2026100111262868500_bib27","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026100111262868500_bib28","doi-asserted-by":"crossref","first-page":"101392","DOI":"10.1016\/j.lanepe.2025.101392","article-title":"Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial","volume":"56","author":"Bryant","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"2026100111262868500_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2026100111262868500_bib30","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/ckj\/sfaa241","article-title":"Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal","volume":"14","author":"Duineveld","year":"2021","journal-title":"Clin Kidney J"},{"issue":"4","key":"2026100111262868500_bib31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"13","key":"2026100111262868500_bib32","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2020006931","article-title":"Familial risk of developing atypical hemolytic-uremic syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026100111262868500_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2026100111262868500_bib34","doi-asserted-by":"crossref","first-page":"370426","DOI":"10.1155\/2012\/370426","article-title":"Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects","volume":"2012","author":"Bu","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"2026100111262868500_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2026100111262868500_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"2026100111262868500_bib37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int"},{"key":"2026100111262868500_bib38","first-page":"2738723","article-title":"Successful subsequent pregnancy in a woman receiving eculizumab for pregnancy-associated atypical haemolytic uraemic syndrome","volume":"2019","author":"Bateman","year":"2019","journal-title":"Case Rep Nephrol"},{"issue":"12","key":"2026100111262868500_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.14740\/jmc3397","article-title":"Eculizumab maintenance and the prevention of atypical hemolytic uremic syndrome relapse during pregnancy: a case report","volume":"10","author":"Winchester","year":"2019","journal-title":"J Med Cases"},{"issue":"12","key":"2026100111262868500_bib40","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.ekir.2020.09.045","article-title":"Eculizumab in early-stage pregnancy","volume":"5","author":"Morales","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2026100111262868500_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40620-018-0517-z","article-title":"Eculizumab in pregnancy: a narrative overview","volume":"32","author":"Sarno","year":"2019","journal-title":"J Nephrol"},{"issue":"1","key":"2026100111262868500_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518171","article-title":"Pregnancy in women with atypical hemolytic uremic syndrome","volume":"146","author":"Rondeau","year":"2022","journal-title":"Nephron"},{"issue":"11","key":"2026100111262868500_bib43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2026100111262868500_bib44","doi-asserted-by":"crossref","first-page":"e001286","DOI":"10.1136\/bmjno-2025-001286","article-title":"Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report","volume":"7","author":"Jacob","year":"2025","journal-title":"BMJ Neurol Open"},{"issue":"9","key":"2026100111262868500_bib45","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/bloodadvances.2025019253","article-title":"Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy","volume":"10","author":"H\u00f6chsmann","year":"2026","journal-title":"Blood Adv"},{"issue":"3","key":"2026100111262868500_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/jcm8030407","article-title":"The extended use of eculizumab in pregnancy and complement activation\u2013associated diseases affecting maternal, fetal and neonatal kidneys\u2014the future is now?","volume":"8","author":"Stefanovic","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"2026100111262868500_bib47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2025.09.033","article-title":"Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments","volume":"109","author":"Praga","year":"2026","journal-title":"Kidney Int"},{"issue":"6","key":"2026100111262868500_bib48","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"2026100111262868500_bib49","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","article-title":"Thrombotic microangiopathy in patients with malignant hypertension","volume":"38","author":"Cavero","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2026100111262868500_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/imr.13131","article-title":"Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases","volume":"313","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2023","journal-title":"Immunol Rev"},{"issue":"suppl 11","key":"2026100111262868500_bib51","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"2026100111262868500_bib52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","article-title":"Expert statements on the standard of care in critically Ill adult patients with atypical hemolytic uremic syndrome","volume":"152","author":"Azoulay","year":"2017","journal-title":"Chest"},{"issue":"4","key":"2026100111262868500_bib53","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2025.01.026","article-title":"Thrombotic microangiopathy after kidney transplantation: insights into genetic etiology and clinical outcomes","volume":"10","author":"Merzkani","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"2","key":"2026100111262868500_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajt.2025.08.019","article-title":"Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post-C5 inhibitor era","volume":"26","author":"Drapeau","year":"2026","journal-title":"Am J Transplant"},{"issue":"7","key":"2026100111262868500_bib55","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ajt.2024.01.029","article-title":"De novo thrombotic microangiopathy after kidney transplantation in adults: interplay between complement genetics and multiple endothelial injury","volume":"24","author":"Dessaix","year":"2024","journal-title":"Am J Transplant"},{"issue":"1","key":"2026100111262868500_bib56","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12882-023-03326-8","article-title":"Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology","volume":"24","author":"Von Tokarski","year":"2023","journal-title":"BMC Nephrol"},{"issue":"5","key":"2026100111262868500_bib57","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.0000000645","article-title":"Post-transplant thrombotic microangiopathy","volume":"36","author":"Java","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2026100111262868500_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/hematology.2024000543","article-title":"Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy","volume":"2024","author":"Java","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2026100111262868500_bib59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ajt.2023.02.020","article-title":"Genetic evaluation of living kidney donor candidates: a review and recommendations for best practices","volume":"23","author":"Thomas","year":"2023","journal-title":"Am J Transplant"},{"issue":"2","key":"2026100111262868500_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajt.2024.10.019","article-title":"Evaluation for genetic disease in kidney transplant candidates: A practice resource","volume":"25","author":"Ames","year":"2025","journal-title":"Am J Transplant"},{"issue":"3","key":"2026100111262868500_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/TP.0000000000005135","article-title":"Kidney transplantation in patients with aHUS: a comparison of eculizumab prophylaxis versus rescue therapy","volume":"109","author":"Duineveld","year":"2025","journal-title":"Transplantation"},{"issue":"3","key":"2026100111262868500_bib62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"issue":"23","key":"2026100111262868500_bib63","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2026100111262868500_bib64","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026100111262868500_bib65","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.ekir.2024.04.022","article-title":"Ex vivo C5b-9 deposition test to monitor complement activity in clinical and subclinical atypical hemolytic uremic syndrome and in transplantation-associated thrombotic microangiopathy","volume":"9","author":"Martin","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"2026100111262868500_bib66","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026100111262868500_bib67","doi-asserted-by":"crossref","first-page":"103717","DOI":"10.1016\/j.ekir.2025.103717","article-title":"Complement alternative pathway dominance in atypical hemolytic uremic syndrome revealed by endothelial bioassays","volume":"11","author":"Santarsiero","year":"2026","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2026100111262868500_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ekir.2023.10.003","article-title":"Ex vivo test of complement dysregulation in atypical hemolytic uremic syndrome kidney transplant patients: a pilot study","volume":"9","author":"Duineveld","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026100111262868500_bib69","doi-asserted-by":"crossref","first-page":"860689","DOI":"10.3389\/fimmu.2022.860689","article-title":"Ex vivo test for measuring complement attack on endothelial cells: from research to bedside","volume":"13","author":"Meuleman","year":"2022","journal-title":"Front Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/14\/1763\/2593357\/blood_bld-2026-033525-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/14\/1763\/2593357\/blood_bld-2026-033525-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:26:45Z","timestamp":1790868405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/14\/1763\/569799\/How-I-treat-thrombotic-microangiopathy-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":69,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033525","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,1]]},"published":{"date-parts":[[2026,10,1]]}}}